Zaid Ammari
Cardiovascular Disease · Newark, DENPI 1003299843
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,622 of the $1,919 with a category attached, or 84.6%. 6 manufacturers reported payments, led by Abbott at 48.0% of the total. Reporting peaked in 2020 at $559 and has fallen 57.1% since, to $240 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in DE, where the typical reported total is $2,459.
Across 66 payments — averaging $29.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$922
- AstraZeneca$406
- E.r. Squibb & Sons, L.L.C.$241
- Boston Scientific$199
- Amgen$134
- Lantheus Medical Imaging, Inc.$17
What the payments were for
- Food & beverage$1,62285%
- Education$29615%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 47 | $922 |
| AstraZeneca | 5 | $406 |
| E.r. Squibb & Sons, L.L.C. | 9 | $241 |
| Boston Scientific | 3 | $199 |
| Amgen | 1 | $134 |
| Lantheus Medical Imaging, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$250
- Ensite Cardiac Mapping System$217
- Tavneos$134
- BRILINTA$125
- ELIQUIS$118
How this compares
$1,919 in reported general payments places this provider in the 45th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Newark
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Anthony AlfieriNewark$45K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Anthony ClayNewark$37K
- Ashish ParikhNewark$26K
- William WeintraubNewark$24K
- Wen Chi TsaiNewark$20K
- Stephen MengNewark$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.